Dr Dusko Ilic
Senior Lecturer in Stem Cell Science
Dr Dusko Ilic obtained his MD degree and BSci in Molecular Biology at the University of Belgrade. He then undertook his PhD at Tokyo University, Japan, and did his postdoctoral work at the University of California in San Francisco. He held position of Adjunct Associate Professor at the University of California San Francisco and Consultant at the Veteran Affairs Medical Center, San Francisco.
He focused his research on the regulation of cellular functions by extracellular matrix in physiological and pathological conditions, specifically oncology. From 2005-2009 he worked as the Director of R&D at StemLifeLine, a California-licensed, state-of-the-art cell culture facility that followed current good tissue practices (cGTP) for derivation and the long-term cryopreservation of the derived hES cell lines. In 2009, Dr Ilic joined King’s College as Senior Lecturer in Stem Cell Science in the Assisted Conception Unit at Guy’s Hospital.
He is coordinator of the cross-divisional postgraduate program in Stem Cells and Regenerative Medicine and Head of the iPS cell core facility at Guy’s Campus. He serves on the editorial board of the journal Regenerative Medicine. His research interest lies in hES cells, iPS cells, cancer stem cells, and regenerative medicine. Key objectives of his work are to raise the standard in derivation and culture of hES cells making them acceptable for cell-based therapies, to understand the molecular mechanisms of diseases using stem cells, and to realize the potential of normal and specific mutation-carrying pluripotent stem cells in drug discovery.
Staff
Students
King's hES cell lines catalogue
Please see the King's hES cell lines catalogue.
For more information and availability contact:
Dr Dusko Ilic
Email: dusko.ilic@kcl.ac.uk
Selected recent publications
2012
-
Ilic D, Polak J. Stem cell based therapy—where are we going? Lancet. 2012; 379: 877-878.
-
Ilic D, Stephenson E, Wood V, Jacquet L, Stevenson D, Petrova A, et al. Derivation and feeder-free propagation of human embryonic stem cells under xeno-free conditions. Cytotherapy. 2012. 14 (1):122-8. [PubMed]
-
Ilic D. Industry Update: Latest developments in stem cell research and regenerative medicine. Regen Med 2012;7: 269-73.
-
Ilic D, Miere C, Lazic E. Umbilical cord blood stem cells: clinical trials in non-hematological disorders. Br Med Bull 2012.
-
Ilic D, Polak J. Stem cell based therapy--where are we going? Lancet 2012;379: 877-8.
-
Ilic D, Stephenson E, Wood V, Jacquet L, Stevenson D, Petrova A, Kadeva N, Codognotto S, Patel H, Semple M, Cornwell G, Ogilvie C, Braude P. Derivation and feeder-free propagation of human embryonic stem cells under xeno-free conditions. Cytotherapy 2012;14: 122-8.
2011
-
Ilic D. Global update: England and Wales. Regen Med. 2011;6(6 Suppl):144-7. [PubMed]
-
Ilic D. Industry highlights: Stem cell and regenerative medicine. Regen Med. 2011;6(6 Suppl):55-60. [PubMed]
-
Maeda T, Sakabe T, Sunaga A, Sakai K, Rivera AL, Keene DR, et al. Conversion of mechanical force into TGF-β-mediated biochemical signals. Curr Biol. 2011;21(11):933-41. [PubMed]
-
Giritharan G, Ilic D, Gormley M, Krtolica A. Human embryonic stem cells derived from embryos at different stages of development share similar transcription profiles. PLoS One. 2011;6(10):e26570. [PubMed]
-
Ilic D, Polak JM. Stem cells in regenerative medicine: introduction. Br Med Bull. 2011;98:117-26. [PubMed]
-
Krtolica A, Larocque N, Genbacev O, Ilic D, Coppe JP, Patil CK, et al. GROalpha regulates human embryonic stem cell self-renewal or adoption of a neuronal fate. Differentiation. 2011;81(4):222-32. [PubMed]
2010
-
Stephenson E, Ogilvie CM, Patel H, Cornwell G, Jacquet L, Kadeva N, Braude P, Ilic D. Safety paradigm: genetic evaluation of therapeutic grade human embryonic stem cells. J R Soc Interface 2010; 7 Suppl 6:S677-88. [PubMed]
-
Petrova A, Ilic D, McGrath JA. Stem cell therapies for recessive dystrophic epidermolysis bullosa. Br J Dermatol 2010;163(6):1149-qq56 [PubMed]
-
Ilic D, Caceres E, Lu S, Julian P, Foulk R, Krtolica A. Effect of karyotype on successful human embryonic stem cell derivation. Stem Cells Dev 2010;19(1):39-46. [PubMed]
2009
-
Ilic D, Giritharan G, Zdravkovic T, Caceres E, Genbacev O, Fisher SJ, Krtolica A. Derivation of human embryonic stem cell lines from biopsied blastomeres on human feeders with minimal exposure to xenomaterials. Stem Cells Dev 2009;18(9):1343-50. [PubMed]
-
Krtolica A, Ilic D, Genbacev O, Miller RK. Human embryonic stem cells as a model for embryotoxicity screening. Regen Med 2009;4(3):449-459. [PubMed]
2008
-
Howerton K, Schlaepfer DD, Ilic D. Establishment of cell lines from mouse embryos with early embryonic lethality. Cell Commun Adhes 2008;15(4):379-383. [PubMed]
-
Chung Y, Klimanskaya I, Becker S, Li T, Maserati M, Lu SJ, Zdravkovic T, Ilic D, Genbacev O, Fisher S, Krtolica A, Lanza R. Human embryonic stem cell lines generated without embryo destruction. Cell Stem Cell 2008;7(2):113-117. [PubMed]
-
Lim ST, Chen XL, Lim Y, Hanson DA, Vo TT, Howerton K, Larocque N, Fisher SJ, Schlaepfer DD, Ilic D. Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation. Mol Cell 2008;29(1):9-22. [PubMed]
-
Salaway T, Ilic D. Logistics of stem cell isolation, preparation and delivery for heart repair: concerns of clinicians, manufacturers, investors and public health. Regen Med 2008;3(1):83-91. [PubMed]
-
Ilic D. Culture of human embryonic stem cells and the extracellular matrix microenvironment. Regen Med 2006;1(1):95-101. [PubMed]
Selected bookchapters
-
Ilic D, Kapidzic M, Genbacev O. Isolation of human placental fibroblasts. Curr Protoc Stem Cell Biol 2008;Chapter 1:Unit 1C.6. [PubMed]
-
Ilic D, Genbacev O, Krtolica A. Derivation of hESC from intact blastocysts. Curr Protoc Stem Cell Biol 2007;Chapter 1:Unit 1A.2. [PubMed]